

Supplementary Table I. The percentages of GR α , GR β , GR γ , GR-P expression in SLE and controls (%).

Group	GR α	GR β	GR γ	GR-P
SLE	51.85(15.43-69.72)*	0.03(0.01-0.12)	13.08(8.51-40.09)	23.78(6.46-40.09)*
control	68.85(41.86-84.32)	0.20(0.02-1.10)	11.63(0.91-33.87)	12.27(8.06-34.96)

* $p < 0.05$ was considered significant.

Supplementary Table II. GR transcripts (GR α , GR β , GR γ , and GR-P) and SRp30c, SRp40 mRNA expression in 28 patients before and after GC treatment.

Variable	BGT	AGT	<i>p</i> -value
GR α	11.25 (10.94-22.65)	21.23 (16.01-29.11)	0.020*
GR β	1.35 (0.43-4.38)	2.74 (0.29-4.49)	0.852
GR γ	2.92 (1.30-4.43)	4.17 (2.53-5.67)	0.118
GR-P	6.55 (2.25-14.12)	6.38 (4.06-13.28)	0.469
SRp30c	13.69 (10.18-18.58)	16.68 (11.48-21.94)	0.367
SRp40	50.00 (32.58-67.78)	90.45 (55.63-190.39)	0.008*

BGT: before GC treatment; AGT: after GC treatment. * $p < 0.05$ was considered significant.

Supplementary Table III. GR transcripts (GR α , GR β , GR γ , and GR-P) and SRp30c, SRp40 mRNA expression between GCS and GCR groups after GC treatment.

Variable	GCS (n=20)	GCR(n=8)	<i>p</i> -value
GR α	21.70 (16.73-33.11)	18.72 (9.58-21.63)	0.097
GR β	2.54 (0.19-6.59)	1.56 (0.88-4.90)	0.222
GR γ	3.07 (2.03-5.54)	5.03 (4.28-9.42)	0.310
GR-P	5.37 (2.19-8.58)	14.33 (6.16-26.00)	0.016*
SRp30c	16.18 (11.94-20.91)	18.52 (12.97-31.31)	0.730
SRp40	78.86 (60.63-142.99)	133.69 (32.32-236.66)	0.629

GCR: glucocorticoid resistant group; GCS: glucocorticoid sensitive group; * $p < 0.05$ was considered significant.